Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Asset Resilience Ratio
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd asset resilience ratio. Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has an Asset Resilience Ratio of 9.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300357 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2014–2024)
Asset resilience ratio of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2014 to 2024. This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read 300357 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥286.82 Million | 9.91% |
| Total Liquid Assets | CN¥286.82 Million | 9.91% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Wolwo Bio-Pharmaceutical Co Ltd maintains only 9.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
Novo Nordisk A/S
CO:NOVO-B |
Drug Manufacturers - General | 0.09% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR |
Drug Manufacturers - General | 0.07% |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2014–2024)
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.24% | CN¥196.09 Million ≈ $28.69 Million |
CN¥2.71 Billion ≈ $396.43 Million |
+2.66pp |
| 2023-12-31 | 4.58% | CN¥117.39 Million ≈ $17.18 Million |
CN¥2.56 Billion ≈ $374.93 Million |
-8.84pp |
| 2022-12-31 | 13.42% | CN¥295.05 Million ≈ $43.18 Million |
CN¥2.20 Billion ≈ $321.62 Million |
-5.78pp |
| 2021-12-31 | 19.20% | CN¥370.93 Million ≈ $54.28 Million |
CN¥1.93 Billion ≈ $282.71 Million |
+0.07pp |
| 2020-12-31 | 19.13% | CN¥307.03 Million ≈ $44.93 Million |
CN¥1.60 Billion ≈ $234.83 Million |
+16.24pp |
| 2019-12-31 | 2.90% | CN¥41.37 Million ≈ $6.05 Million |
CN¥1.43 Billion ≈ $208.99 Million |
-8.07pp |
| 2018-12-31 | 10.97% | CN¥116.00 Million ≈ $16.97 Million |
CN¥1.06 Billion ≈ $154.80 Million |
-24.40pp |
| 2017-12-31 | 35.36% | CN¥300.00 Million ≈ $43.90 Million |
CN¥848.31 Million ≈ $124.13 Million |
+10.83pp |
| 2016-12-31 | 24.54% | CN¥171.00 Million ≈ $25.02 Million |
CN¥696.89 Million ≈ $101.98 Million |
+8.18pp |
| 2015-12-31 | 16.35% | CN¥100.00 Million ≈ $14.63 Million |
CN¥611.49 Million ≈ $89.48 Million |
+5.06pp |
| 2014-12-31 | 11.29% | CN¥60.00 Million ≈ $8.78 Million |
CN¥531.31 Million ≈ $77.75 Million |
-- |
About Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; and Changdian, a dust mite skin prick diagnost… Read more